Skip to main content
# Title Department Research Year
161 The inhibitory coreceptor CD22 restores B cell signaling by developmentally regulating Cd45 −/− immunodeficient B cells Department of Pharmaceutical Organic Chemistry 2022
162 Synthesis of novel amidines via one-pot three component reactions: Selective topoisomerase I inhibitors with antiproliferative properties 2022
163 Clinical translation of nanomedicines: Challenges, opportunities, and keys Department of Industrial Pharmacy 2022
164 Exploration of components contributing to potent cytotoxicity of Gardenia thunbergia L. f. against human leukemia and hepatoma Department of Pharmacognosy 2022
165 Design and optimization of PEGylated silver nanoparticles for efficient delivery of Doxorubicin to cancer cells Department of Industrial Pharmacy 2022
166 Evaluation of Different Surface Coating Agents for Selenium Nanoparticles: Enhanced Anti-Inflammatory Activity and Drug Loading Capacity Department of Pharmaceutics 2022
167 Dual Targeting of Steroid Sulfatase and 17β-Hydroxysteroid Dehydrogenase Type 1 by a Novel Drug-Prodrug Approach: A Potential Therapeutic Option for the Treatment of Endometriosis Department of Pharmaceutical Organic Chemistry 2022
168 Synthesis, computational study and biological evaluation of 9-acridinyl and 1-coumarinyl-1, 2, 3-triazole-4-yl derivatives as topoisomerase II inhibitors Department of Medicinal Chemistry 2022
169 Combinatorial Therapy of Letrozole- and Quercetin-Loaded Spanlastics for Enhanced Cytotoxicity against MCF-7 Breast Cancer Cells Department of Pharmaceutics 2022
170 Structure-based design, synthesis and antiproliferative action of new quinazoline-4-one/chalcone hybrids as EGFR inhibitors Department of Pharmaceutical Organic Chemistry 2022